Dr. Tapan Kadia, MD
Claim this profileM D Anderson Cancer Center
Expert in Childhood Cancer
Expert in Acute Myeloid Leukemia
24 reported clinical trials
37 drugs studied
About Tapan Kadia, MD
Education:
- Obtained MD from Baylor College of Medicine, Houston, Texas, in 2005.
- Completed Residency in Internal Medicine at The Johns Hopkins Hospital, Baltimore, Maryland (2005-2008).
- Undertook Fellowship in Hematology/Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas (2008-2011).
Experience:
- Currently serves as a Professor of Medicine and Chief of the Section of Leukemia at The University of Texas MD Anderson Cancer Center.
Area of expertise
1Childhood Cancer
Global LeaderHLA
prior malignancy
myelodysplastic syndrome
2Acute Myeloid Leukemia
Global LeaderHLA
prior malignancy
myelodysplastic syndrome
Affiliated Hospitals
Clinical Trials Tapan Kadia, MD is currently running
APG-2575 + Azacitidine
for Acute Myeloid Leukemia
This trial is testing a new drug (APG-2575) combined with an existing drug (Azacitidine) to treat certain blood cancers that have not responded to other treatments. The goal is to see if this combination can more effectively kill cancer cells.
Recruiting1 award Phase 1 & 23 criteria
Liposomal Daunorubicin-Cytarabine + Venetoclax
for Acute Myeloid Leukemia
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Recruiting1 award Phase 2
More about Tapan Kadia, MD
Clinical Trial Related5 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Tapan Kadia, MD has experience with
- Venetoclax
- Decitabine
- Cladribine
- Cytarabine
- APG-2575
- Azacitidine
Breakdown of trials Tapan Kadia, MD has run
Childhood Cancer
Acute Myeloid Leukemia
Granulocytic Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tapan Kadia, MD specialize in?
Tapan Kadia, MD focuses on Childhood Cancer and Acute Myeloid Leukemia. In particular, much of their work with Childhood Cancer has involved HLA patients, or patients who are prior malignancy.
Is Tapan Kadia, MD currently recruiting for clinical trials?
Yes, Tapan Kadia, MD is currently recruiting for 11 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Tapan Kadia, MD has studied deeply?
Yes, Tapan Kadia, MD has studied treatments such as Venetoclax, Decitabine, Cladribine.
What is the best way to schedule an appointment with Tapan Kadia, MD?
Apply for one of the trials that Tapan Kadia, MD is conducting.
What is the office address of Tapan Kadia, MD?
The office of Tapan Kadia, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.